Navigation Links
Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
Date:12/5/2010

a (SLL): An Update on Ongoing Phase 1 Studies" is being presented by Jan Burger MD, PhD. This abstract describes clinical data from a pooled analysis of 54 CLL/SLL patients from a Phase Ia (N=16) and a Phase Ib/II (N=38) study.  Patients from the Phase Ia trial have relapsed/refractory CLL/SLL and have been treated for a median of approximately 8 months, while patients on the Phase Ib/II trial include two cohorts—one with relapsed or refractory disease and one with treatment-naive disease—who were just recently enrolled.

Response data from the pooled analysis is presented below.  Outcomes are described based on strict application of standard response criteria, with an additional outcome category termed "nodal response with lymphocytosis." This category describes patients with substantial lymph node (LN) shrinkage who have not yet achieved a 50% decrease of malignant B cells in the blood (lymphocytosis). The inclusion of this category is necessary because of the unique characteristics of response to this agent, especially early in treatment.  From the Ia trial, with approximately 8 months median follow-up, 1 patient achieved a complete response (CR) and 8/13 evaluable patients achieved a partial response (PR) for an objective response rate of 69%. Two additional patients achieved a nodal response with lymphocytosis (15%) and 2 patients had stable disease (SD).  Of note, 3 of the patients now classified as partial responses were initially nodal response with lymphocytosis earlier in treatment. In the Ib/II trial, with less than 2 months median follow-up, 8/32 evaluable patients achieved a PR (25%) by standard response criteria with an additional 17/32 (53%) achieving a nodal response with lymphocytosis.  Six other patients have SD. As noted previously, study of the patients from the Ia trial suggest that blood lymphocytosis decreases over time on treatment and patients who initially are described as nodal responses with lym
'/>"/>

SOURCE Pharmacyclics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
2. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
3. Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
4. Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
5. Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results
6. Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7
7. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
8. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
11. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... LONDON , July 11, 2014 ... ended at 4,396.20, down 0.52%, the Dow Jones Industrial Average ... 500 closed at 1,964.68, down 0.41%. The losses were broad ... in negative. The S&P 500 Health Care Sector Index ended ... advanced 2.75% in the last one month. Investor-Edge has initiated ...
(Date:7/11/2014)... According to a new market ... (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) - Global ... the global endoscopy devices market was valued at USD ... at a CAGR of 6.8% from 2013 to 2019, ... in 2019. Browse the full Endoscopy Devices Market ...
(Date:7/11/2014)... , July 11, 2014 Research ... addition of the "Immunoprotein Diagnostic Testing Market ... the highest CAGR of 6% and is expected ... report to their offering. ... immunoprotein diagnostic testing has been segmented according to ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... Inc. (Nasdaq: CALP ) will conduct a ... results at 9:00 a.m. ET on Thursday, October 28. ... McAree, Chief Financial Officer, will host the call. Management ... outlook for the future. A news ...
... Oct. 14 OrthoAccel Technologies, Inc., developers of ... to enhance orthodontics, announced this week that it ... its Corporate Board.  Mr. Cooper,s directorship will involve ... strategy, with a focus on market growth. ...
Cached Medicine Technology:Caliper Life Sciences' Third Quarter 2010 Financial Results Conference Call Notice 2Medical Device Industry Executive Joins OrthoAccel Technologies, Inc. Board of Directors 2Medical Device Industry Executive Joins OrthoAccel Technologies, Inc. Board of Directors 3
(Date:7/11/2014)... As reported by Forbes in the article Robert ... Blame (6/30), Indino Downey has reportedly been arrested after ... it with. His father, well-known actor Robert Downey Jr. ... him may have something to do with his addiction ... 1980s and 1990s for substance abuse before finally getting ...
(Date:7/11/2014)... Los Angeles, CA (PRWEB) July 11, 2014 ... Kevin Sands today announces that he uses mini and ... these treatments offer the defining feature that distinguishes dental ... of teeth in addition to the crowns. This alone ... dental implants also offer advantages related to comfort, ...
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- Polio is history ... places like Afghanistan, Nigeria and Pakistan. Giving vaccinated children ... their immunity and help eradicate the highly infectious disease, ... is highly effective, immunity wanes as early as a ... be infected and contribute to the spread of the ...
(Date:7/11/2014)... breast cancer patients, the era of personalized medicine may ... by USC Stem Cell researcher Min Yu and scientists ... In a July 11 study in Science , ... cancer cells circulating through the blood streams of six ... "seeds" of metastasis, which travel to and establish secondary ...
(Date:7/11/2014)... American Farmer is proud to announce their latest ... at 8:30 am ET. , In this episode, American ... designed and formulated for use on a wide range ... help the crop realize its maximum genetic yield potential ... The show also features UniSouth Genetics, a non-profit co-op ...
Breaking Medicine News(10 mins):Health News:Roberty Downey's Son Arrested For Cocaine 2Health News:Dental Implant Dentist, Kevin Sands DDS, Now Uses Mini and Full Mouth Implants to Replace Missing Teeth 2Health News:Researchers Assess New Way to Boost Polio Immunity 2Health News:New Episode of American Farmer Featuring Sunbelt, UniSouth Genetics, and Michigan Milk Producers Association Airing on RFD-TV 2
... ... pleased to announce the appointment of Kim Eldridge RNFA, CFCN, WCC as ... 10 years of clinical experience in complex wound care, is a pioneer ... highest standards of care, improving clinical outcomes, emphasizing patient education, and ensuring ...
... It is estimated that ... unaware of their rights, if Yaz, the most popular birth control pill in the United States, ... or the families of women who have suffered from serious health problems after taking Yaz. ... St. Louis, MO (Vocus) November 12, 2009 ...
... Regence BlueCross BlueShield has been recognized as a Platinum-Level ... movement for helping employees eat better and move more. ... priorities at Regence," said Mark Ganz, Regence president and ... possible and helping our employees lead healthier lives. We ...
... Nov. 12 In response to recent fears of ... has partnered with UC Berkeley,s Center for Infectious Disease ... seminars statewide helping employers protect their workforces and business ... extremely important that business leaders educate themselves and prepare ...
... AMICAS, Inc. (Nasdaq: AMCS ), a leader ... it will showcase the intrinsic mammography capabilities of AMICAS ... (RSNA) annual meeting from November 29 to December 4 ... Hall in booth #7124. , (Logo: http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ...
... 12 Bioniche Pharma, a leading developer and ... of Duraclon® (clonidine hydrochloride injection) and Methadone Hydrochloride ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO ) , "Bioniche Pharma ... with these injectable drugs," said Steve Thornton, Bioniche ...
Cached Medicine News:Health News:Wake Pharma US, Inc. Announces the Appointment of Kim Eldridge as Coordinator & Clinical Wound Specialist Educator 2Health News:Yaz and Yasmin Birth Control Lawsuits Continue to Mount,The Onder Law Firm Will Provide a Free Case Review to Women Suffering from Yaz Side Effects 2Health News:Yaz and Yasmin Birth Control Lawsuits Continue to Mount,The Onder Law Firm Will Provide a Free Case Review to Women Suffering from Yaz Side Effects 3Health News:Regence Recognized as an American Heart Association Start! Fit-Friendly Company 2Health News:Regence Recognized as an American Heart Association Start! Fit-Friendly Company 3Health News:AMICAS PACS For Mammography at RSNA 2009 2Health News:AMICAS PACS For Mammography at RSNA 2009 3Health News:Bioniche Pharma Acquires Duraclon(R) (clonidine hydrochloride injection) and Methadone Hydrochloride Injection USP 2
... Plate is a semi-rigid system intended ... The Slim-LOC is based on the ... current market technology. The Slim-LOCTM system ... instrumentation. Reduced width (16 mm), low ...
... SC-Acufix anterior cervical plate system is a ... integrated swivel, which provides for consistent, reliable ... bone screw disengagement or backout. This innovative ... locking screw. Simply implant your screws and ...
... a leading provider of telemedicine solutions. ... state-of-the-art technology deliver accurate, reliable and ... professionals and clients in improving outcomes. ... ECG technology to gather patient data, ...
... is a high performance temperature controlled shaker ... shaking speed and incubation time are fully ... parameters are displayed on the LCD in ... below the microplates provide uniform incubation with ...
Medicine Products: